MedTrace Logo

CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia

NCT03854994 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-02-26

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the safety and clinical activity of anti-CD19 Chimeric Antigen Receptor T cells (KD-019 CAR-T)infusion in the treatment of relapsed/refractory B-cell Lymphoma and B-cell acute lymphoblastic leukemia （B-ALL）.

Conditions

Interventions

BIOLOGICAL

Anti-CD19 CAR-T Cells Injection

Autologous genetically modified anti-CD19 CAR transduced T cells

Sponsors & Collaborators

  • KAEDI

    collaborator OTHER

  • Yan'an Affiliated Hospital of Kunming Medical University

    lead OTHER

Principal Investigators

  • Peixian Zhang · Kunming Yan'an Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2021-08-01
Completion
2022-08-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03854994 on ClinicalTrials.gov